Briumvi’s Phase 3 trial of an at-home injection has completed enrollment, testing an under-the-skin version against IV ...
Abstract: The development of high-performance, low-cost O-band multi- wavelength light sources has become increasingly critical, largely driven by the exponential bandwidth growth in short-reach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results